Erratum to "Thymosin alpha1 enhanced cytotoxicity of iNKT cells against colon cancer via upregulating CD1d expression" [Cancer Lett. 356/2PB (2015) 579-588], Doi: 10.1016/j.canlet.2014.10.002;Thymosin alpha1 enhanced cytotoxicity of iNKT cells against colon cancer via upregulating CD1d expression

Cancer Letters

Volumn 356, Issue 2, 2015, Pages 579-588

  Ni, Chao ^a,b   Wu, Pin ^b   Wu, Xianguo ^b   Zhang, Ting ^b   Zhang, Tao ^b   Wang, Zhen ^b   Zhang, Sai ^b   Qiu, Fuming ^b   Huang, Jian ^b  

^a ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Cancer stem cells; CD1d; Colon cancer; Invariant NKT cells; Thymosin alpha 1

Indexed keywords

ALPHA GALCER; B7 ANTIGEN; CD1D ANTIGEN; IMMUNOLOGICAL ADJUVANT; INDUCIBLE T CELL COSTIMULATOR LIGAND; MITOGEN ACTIVATED PROTEIN KINASE; THYMOSIN ALPHA1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CD1D PROTEIN, HUMAN; MESSENGER RNA; THYMOSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER STEM CELL; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOASSAY; IN VITRO STUDY; IN VIVO STUDY; INVARIANT NATURAL KILLER T CELL; MOLECULAR RECOGNITION; MOUSE; NATURAL KILLER T CELL; NEUTRALIZATION ASSAY; NONHUMAN; T LYMPHOCYTE ACTIVATION; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; APOPTOSIS; CELL PROLIFERATION; COCULTURE; COLON TUMOR; DRUG SCREENING; ENZYME IMMUNOASSAY; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCID MOUSE; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; ANTIGENS, CD1D; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; COCULTURE TECHNIQUES; COLONIC NEOPLASMS; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MICE, INBRED NOD; MICE, SCID; NATURAL KILLER T-CELLS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THYMOSIN; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84919460038     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.02.034     Document Type: Erratum

References (44)

1. Siegel R., Ward E., Brawley O., Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J. Clin 2011, 61(4):212-236.
2. Deschoolmeester V., Baay M., Van Marck E., Weyler J., Vermeulen P., Lardon F., et al. Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients. BMC Immunol 2010, 11:19.
3. Bauer K., Michel S., Reuschenbach M., Nelius N., von Knebel Doeberitz M., Kloor M. Dendritic cell and macrophage infiltration in microsatellite-unstable and microsatellite-stable colorectal cancer. Fam. Cancer 2011, 10(3):557-565.
4. Ellebaek E., Andersen M.H., Svane I.M., Straten P.T. Immunotherapy for metastatic colorectal cancer: present status and new options. Scand. J. Gastroenterol 2012, 47(3):315-324.
5. Goldstein A.L., Low T.L., McAdoo M., McClure J., Thurman G.B., Rossio J., et al. Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proc. Natl. Acad. Sci. U.S.A. 1977, 74(2):725-729.
6. Goldstein A.L., Goldstein A.L. From lab to bedside: emerging clinical applications of thymosin alpha 1. Expert Opin. Biol. Ther 2009, 9(5):593-608.
7. Moody T.W., Fagarasan M., Zia F., Cesnjaj M., Goldstein A.L. Thymosin alpha 1 down-regulates the growth of human non-small cell lung cancer cells in vitro and in vivo. Cancer Res 1993, 53(21):5214-5218.
8. Garaci E., Pica F., Serafino A., Balestrieri E., Matteucci C., Moroni G., et al. Thymosin alpha1 and cancer: action on immune effector and tumor target cells. Ann. N. Y. Acad. Sci 2012, 1269:26-33.
9. Giuliani C., Napolitano G., Mastino A., Di Vincenzo S., D'Agostini C., Grelli S., et al. Thymosin-alpha1 regulates MHC class I expression in FRTL-5 cells at transcriptional level. Eur. J. Immunol 2000, 30(3):778-786.
10. Terabe M., Berzofsky J.A. The role of NKT cells in tumor immunity. Adv. Cancer Res 2008, 101:277-348.
11. Swann J.B., Uldrich A.P., van Dommelen S., Sharkey J., Murray W.K., Godfrey D.I., et al. Type I natural killer T cells suppress tumors caused by p53 loss in mice. Blood 2009, 113(25):6382-6385.
12. Fallarini S., Paoletti T., Orsi Battaglini N., Lombardi G. Invariant NKT cells increase drug-induced osteosarcoma cell death. Br. J. Pharmacol 2012, 167(7):1533-1549.
13. Liu D., Song L., Brawley V.S., Robison N., Wei J., Gao X., et al. Medulloblastoma expresses CD1d and can be targeted for immunotherapy with NKT cells. Clin. Immunol 2013, 149(1):55-64.
14. Ni C., Wu P., Zhu X., Ye J., Zhang Z., Chen Z., et al. IFN-gamma selectively exerts pro-apoptotic effects on tumor-initiating label-retaining colon cancer cells. Cancer Lett 2013, 336(1):174-184.
15. Nowak M., Arredouani M.S., Tun-Kyi A., Schmidt-Wolf I., Sanda M.G., Balk S.P., et al. Defective NKT cell activation by CD1d+ TRAMP prostate tumor cells is corrected by interleukin-12 with alpha-galactosylceramide. PLoS ONE 2010, 5(6):e11311.
16. Metelitsa L.S. Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans. Clin. Immunol 2011, 140(2):119-129.
17. Abos-Gracia B., del Moral M.G., Lopez-Relano J., Viana-Huete V., Castro L., Villalba M., et al. Olea europaea pollen lipids activate invariant natural killer T cells by upregulating CD1d expression on dendritic cells. J. Allergy Clin. Immunol 2013, 131(5):1393-1399.e5.
18. Durgan K., Ali M., Warner P., Latchman Y.E. Targeting NKT cells and PD-L1 pathway results in augmented anti-tumor responses in a melanoma model. Cancer Immunol. Immunother 2011, 60(4):547-558.
19. Kaneda H., Takeda K., Ota T., Kaduka Y., Akiba H., Ikarashi Y., et al. ICOS costimulates invariant NKT cell activation. Biochem. Biophys. Res. Commun 2005, 327(1):201-207.
20. Sugihara E., Saya H. Complexity of cancer stem cells. Int. J. Cancer 2013, 132(6):1249-1259.
21. Wang Y.K., Zhu Y.L., Qiu F.M., Zhang T., Chen Z.G., Zheng S., et al. Activation of Akt and MAPK pathways enhances the tumorigenicity of CD133+ primary colon cancer cells. Carcinogenesis 2010, 31(8):1376-1380.
22. Wang K., Zhang T., Liu L., Wang X., Wu P., Chen Z., et al. Novel micelle formulation of curcumin for enhancing antitumor activity and inhibiting colorectal cancer stem cells. Int. J. Nanomedicine 2012, 7:4487-4497.
23. Brennan P.J., Brigl M., Brenner M.B. Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions. Nat. Rev. Immunol 2013, 13(2):101-117.
24. Morris E.S., MacDonald K.P., Rowe V., Banovic T., Kuns R.D., Don A.L., et al. NKT cell-dependent leukemia eradication following stem cell mobilization with potent G-CSF analogs. J. Clin. Invest 2005, 115(11):3093-3103.
25. Peng X., Zhang P., Wang X., Chan J., Zhu M., Jiang M., et al. Signaling pathways leading to the activation of IKK and MAPK by thymosin alpha1. Ann. N. Y. Acad. Sci 2007, 1112:339-350.
26. Li M., Feurino L.W., Li F., Wang H., Zhai Q., Fisher W.E., et al. Thymosinalpha1 stimulates cell proliferation by activating ERK1/2, JNK, and increasing cytokine secretion in human pancreatic cancer cells. Cancer Lett 2007, 248(1):58-67.
27. Xiang B., Snook A.E., Magee M.S., Waldman S.A. Colorectal cancer immunotherapy. Discov. Med 2013, 15(84):301-308.
28. Chang D.H., Osman K., Connolly J., Kukreja A., Krasovsky J., Pack M., et al. Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J. Exp. Med 2005, 201(9):1503-1517.
29. Restifo N.P., Dudley M.E., Rosenberg S.A. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat. Rev. Immunol 2012, 12(4):269-281.
30. Parkhurst M.R., Yang J.C., Langan R.C., Dudley M.E., Nathan D.A., Feldman S.A., et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther 2011, 19(3):620-626.
31. Schlimper C., Hombach A.A., Abken H., Schmidt-Wolf I.G. Improved activation toward primary colorectal cancer cells by antigen-specific targeting autologous cytokine-induced killer cells. Clin. Dev. Immunol 2012, 2012:238924.
32. Karlsson M., Marits P., Dahl K., Dagoo T., Enerback S., Thorn M., et al. Pilot study of sentinel-node-based adoptive immunotherapy in advanced colorectal cancer. Ann. Surg. Oncol 2010, 17(7):1747-1757.
33. Gumperz J.E., Miyake S., Yamamura T., Brenner M.B. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J. Exp. Med 2002, 195(5):625-636.
34. Bezbradica J.S., Stanic A.K., Matsuki N., Bour-Jordan H., Bluestone J.A., Thomas J.W., et al. Distinct roles of dendritic cells and B cells in Va14Ja18 natural T cell activation in vivo. J. Immunol 2005, 174(8):4696-4705.
35. Fujii S., Liu K., Smith C., Bonito A.J., Steinman R.M. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J. Exp. Med 2004, 199(12):1607-1618.
36. Garrido F., Ruiz-Cabello F., Cabrera T., Perez-Villar J.J., Lopez-Botet M., Duggan-Keen M., et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol. Today 1997, 18(2):89-95.
37. Liao T., Kaufmann A.M., Qian X., Sangvatanakul V., Chen C., Kube T., et al. Susceptibility to cytotoxic T cell lysis of cancer stem cells derived from cervical and head and neck tumor cell lines. J. Cancer Res. Clin. Oncol 2013, 139(1):159-170.
38. Lai D., Wang F., Chen Y., Wang C., Liu S., Lu B., et al. Human ovarian cancer stem-like cells can be efficiently killed by gammadelta T lymphocytes. Cancer Immunol. Immunother 2012, 61(7):979-989.
39. Todaro M., D'Asaro M., Caccamo N., Iovino F., Francipane M.G., Meraviglia S., et al. Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes. Journal of immunology 2009, 182(11):7287-7296.
40. Iovino F., Meraviglia S., Spina M., Orlando V., Saladino V., Dieli F., et al. Immunotherapy targeting colon cancer stem cells. Immunotherapy 2011, 3(1):97-106.
41. Badamchian M., Mora C.A., Baumann C.A., Paino J.E., Goldstein A.L. Biodistribution of synthetic thymosin alpha1 in the serum, urine and major organs of mice. Int. J. Immunopharmacol 1997, 19(2):59-66.
42. Zhang P., Chan J., Dragoi A.M., Gong X., Ivanov S., Li Z.W., et al. Activation of IKK by thymosin alpha1 requires the TRAF6 signalling pathway. EMBO Rep 2005, 6(6):531-537.
43. Romani L., Bistoni F., Perruccio K., Montagnoli C., Gaziano R., Bozza S., et al. Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Blood 2006, 108(7):2265-2274.
44. Bozza S., Gaziano R., Bonifazi P., Zelante T., Pitzurra L., Montagnoli C., et al. Thymosin alpha1 activates the TLR9/MyD88/IRF7-dependent murine cytomegalovirus sensing for induction of anti-viral responses in vivo. Int. Immunol 2007, 19(11):1261-1270.